HOMCY CHARLES J 4

What Happened
Charles J. Homcy, a director of BridgeBio Pharma, received two awards on June 22, 2026: 3,990 shares reported as shares acquired and 5,277 RSU-type derivative awards, for a total of 9,267 RSUs/contingent share rights. The filing records an acquisition price of $0 for these awards. These are grants (not open‑market purchases or sales) and vest in full on June 22, 2027, subject to Homcy’s continued service on the board.

Key Details

• Transaction date: June 22, 2026; Form 4 filed June 24, 2026 (within the standard reporting window).
• Amounts: 3,990 shares + 5,277 RSU/derivative awards = 9,267 total. Price per share: $0 (award).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes from the filing:
  • F1: Grant of RSUs under the Issuer’s 2021 Amended and Restated Stock Option and Incentive Plan; RSUs vest in full on June 22, 2027, subject to continued board service.
  • F2: Each RSU represents a contingent right to receive one share of common stock.
  • F3: Notes that the shares underlying the stock option vest in full on June 22, 2027, subject to continued board service (as stated in the filing).
• Filing timeliness: Reported two days after the grant date (appears timely).

Context
RSUs are awards that convert into actual shares only upon vesting; this grant does not represent immediate market buying or selling by the insider. Because the awards vest a year out and are contingent on continued board service, they are more of a compensation/governance matter than a direct signal of near‑term insider buying or selling.